PCAS SA provided consolidated earnings guidance for the first half of 2022. For the period, The company Group will generate a further significant current operational loss, still negatively affected by business levels that are still not sufficient to cover the fixed costs incurred at several Pharmaceutical synthesis sites, and inventory depreciations linked to non-compliant productions.